Obinutuzumab in Chinese Real-world Patients With iNHL
ConditionLymphomas Non-Hodgkin's B-Cell
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorAffiliated Hospital of Nantong University
About this trial
This study aims to assess the clinical efficacy and safety of obinutuzumab in Chinese patients with indolent non-Hodgkin B-cell Lymphoma (predominantly Follicular lymphoma and Marginal zone lymphoma) in a real-world setting.
Eligibility criteria
Qualifiers
Age: Age ≥ 18 years at the start of treatment;
Be diagnosed with grade 1-3a follicular Lymphoma, Marginal zone lymphoma;
Previously untreated or relapsed or refractory patients;
Patients who started treatment with otuzumab between June 2021 and April 2023.
Disqualifiers
Patients currently participating or planning to participate in any interventional clinical trial;
Patients who, in the opinion of the investigator, are Discomfort for any other reason to participate in this study.
Trial design
Treatments tested in this trial
- Obinutuzumab
Treatment groups
400 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov